CalciMedica, Inc.
CALC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534133
No open-market purchases or sales by CalciMedica, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $8.39M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in CalciMedica, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +1 vs. Q1 2024
- Shares held
- 2.97M
- −574.6K (−16.2%) vs. Q1 2024
- Total value
- $11.8M
- −$2.99M (−20.2%) vs. Q1 2024
- New holders
- 6
- 3 more added
- Sold out
- 5
- 5 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CALC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $8.39M |
| Q1 2026 | 27 | $592.5K |
| Q4 2025 | 31 | $24.2M |
| Q3 2025 | 31 | $10.9M |
| Q2 2025 | 30 | $5.93M |
| Q1 2025 | 30 | $7.49M |
| Q4 2024 | 29 | $15.1M |
| Q3 2024 | 24 | $13.6M |
| Q2 2024 | 21 | $11.8M |
| Q1 2024 | 20 | $14.8M |
| Q4 2023 | 12 | $1.49M |
| Q3 2023 | 13 | $1.56M |
| Q2 2023 | 13 | $2.72M |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 27 | $5.97M |
| Q3 2022 | 25 | $10.2M |
| Q2 2022 | 25 | $11.7M |
| Q1 2022 | 27 | $13.5M |
| Q4 2021 | 28 | $20.7M |
| Q3 2021 | 27 | $37.0M |
| Q2 2021 | 41 | $63.7M |
| Q1 2021 | 51 | $72.8M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding CalciMedica, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 1,000,000 | $3.96M | 0.07% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 783,904 | $3.10M | 0.27% | 00.0% | Unchanged |
| Aisling Capital Management LP | 521,114 | $2.06M | 0.89% | 00.0% | Unchanged |
| Vanguard Group Inc | 252,801 | $1.00M | 0.00% | +239,442+1,792.4% | Added |
| BML Capital Management, LLC | 160,424 | $635.3K | 0.47% | 00.0% | Unchanged |
| Millennium Management LLC | 61,587 | $243.9K | 0.00% | −4,547−6.9% | Reduced |
| Meritage Portfolio Management | 46,000 | $182.0K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 44,028 | $174.3K | 0.00% | −658−1.5% | Reduced |
| Envestnet Asset Management Inc | 22,256 | $88.1K | 0.00% | +22,256 | New |
| J. Goldman & Co LP | 18,900 | $74.8K | 0.00% | +18,900 | New |
| Tritonpoint Wealth, LLC | 15,119 | $59.9K | 0.01% | +15,119 | New |
| BlackRock Inc. | 13,242 | $52.4K | 0.00% | +13,242 | New |
| First Manhattan Co | 13,226 | $52.4K | 0.00% | 00.0% | Unchanged |
| Atria Investments LLC | 11,207 | $44.4K | 0.00% | +11,207 | New |
| Bank of America Corp | 9,008 | $35.7K | 0.00% | +8,501+1,676.7% | Added |
| Tower Research Capital LLC (TRC) | 921 | $4.61K | 0.00% | −1,260−57.8% | Reduced |
| Morgan Stanley | 856 | $3.39K | 0.00% | 00.0% | Unchanged |
| Brown Brothers Harriman & Co | 308 | $1.22K | 0.00% | +308 | New |
| JPMorgan Chase & Co | 18 | $71 | 0.00% | +4+28.6% | Added |
| UBS Group AG | 15 | $59 | 0.00% | −1−6.3% | Reduced |
| Qube Research & Technologies Ltd | 1 | $4 | 0.00% | −1,228−99.9% | Reduced |
| Stonepine Capital Management, LLC | 0 | $0 | 0.00% | −522,602−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −297,380−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −75,082−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −781−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −55−100.0% | Sold out |